Argireline: research

A topical cosmetic peptide with small, mixed wrinkle studies and limited skin penetration.

Also called: Acetyl hexapeptide-8, Acetyl hexapeptide-8 amide, Acetyl hexapeptide-3 (older name), AH8, Ac-EEMQRR-NH2.

Cosmetic peptides · SNAP-25-mimicking cosmetic hexapeptide.

26 primary human records located, including cases and three registries without results. Small trials and mixed formulas limit confidence.

Studies

• First wrinkle study. open-label, n=10, Healthy women. An early pilot found smoother wrinkles; its size limits confidence. (source)
• Cream versus gel. open-label, n=20, Women aged 40–57 with dry or oily skin. Both moisturizing formulas improved measurements without a placebo comparison. (source)
• Four-week wrinkle trial. rct, n=60, Chinese adults aged 25–60 with eye-area wrinkles. A small trial found more responders than placebo. (source)
• Eyelid-spasm add-on pilot. rct, n=24, Adults receiving regular botulinum toxin for blepharospasm. The add-on pilot did not establish longer toxin benefit. (source)
• Higher-dose eyelid study. rct, n=8, Adults with primary blepharospasm off toxin benefit. The tiny terminated study did not show useful symptom improvement. (source)
• Skin hydration and mechanics. rct, n=40, Healthy women aged 35–55. The peptide changed one skin-mechanics measure; the base also moisturized. (source)
• Multi-peptide routine. open-label, n=29, Women with mild to moderate sun-related facial aging. A combination routine improved appearance in an uncontrolled study. (source)
• Two-peptide comparison. rct, n=24, Healthy adult women. Small-group comparisons do not establish that stacking works better. (source)
• Dissolving microneedle patches. rct, n=52, Korean women with facial wrinkles. A peptide microneedle patch improved one eye-wrinkle measure more than the plain patch. (source)
• Temporary scar camouflage. case-series, n=26, Adults with scars, wrinkles and other skin concerns. A mixed cosmetic temporarily improved appearance in uncontrolled cases. (source)
• Oily-skin pilot. rct, n=14, Adults with oily facial skin. The oily-skin pilot did not establish reduced oil production. (source)
• Crow’s-feet comparison. rct, n=21, Indonesian women aged 26–55. This small comparison did not establish a measurable AH8 benefit. (source)
• Added benefit over hyaluronic acid. cohort, n=19, Women aged 24–68. Argireline did not add a significant benefit to the base serum. (source)
• Multi-peptide eye serum. open-label, n=32, Women aged 20–45; mean age 28.5. A blend improved readings and satisfaction without an AH8-only comparison. (source)
• Retinoid-peptide serum versus laser. open-label, n=71, Women aged 40–65 with facial sun damage. A retinoid-peptide blend improved appearance; it does not establish AH8’s contribution. (source)
• Serum alongside toxin injections. case-series, Cosmetic patients described by dermatologists and surgeons. Clinicians reported combination use; additive efficacy remains uncertain. (source)
• Ionic-liquid delivery cream. cohort, Human cosmetic test participants; number not in accessible abstract. A delivery experiment reports a human comparison with incomplete accessible details. (source)
• Five-active serum: static lines. single-arm, n=74, Chinese women aged 25–55. A five-active serum improved scores from baseline without a control. (source)
• Five-active serum: smile lines. single-arm, n=49, Chinese women; completers aged 38–55. A separate uncontrolled cohort showed modest score changes while smiling. (source)
• Combination routine after toxin. single-arm, n=16, Regular toxin users with facial wrinkles. A small uncontrolled combination study reported longer intervals between injections. (source)
• Experimental three-peptide delivery. cohort, Human exploratory cosmetic participants; n not in abstract. An exploratory clinical claim requires full methods before dosing can be extracted. (source)
• Peptide-loaded thread case. case-report, n=1, One adult cosmetic patient with deep upper-face wrinkles. One procedure example does not establish safe or effective implanted AH8. (source)
• Thai wrinkle study: no posted results. rct, n=70, Adult cosmetic-study participants. A completed registry record has no publicly posted results. (source)
• Multi-ingredient eye serum: no results. single-arm, n=35, Adult cosmetic-study participants. A completed registry record has no publicly posted results. (source)
• Compounded blend: no posted results. rct, n=10, Adult cosmetic-study participants. A completed registry record has no publicly posted results. (source)
• Facial injection infection. case-report, n=1, Adult woman after facial Argireline injections. A serious infection case warns against treating cosmetic AH8 as an injectable. (source)
• Where the peptide reaches. in-vitro, Human cadaver skin and hairless guinea-pig skin. Most peptide stayed outside or in the outer skin. (source)
• Aged-mouse collagen study. animal, D-galactose-aged mice. Collagen changes were measured in mice, not cosmetic trial participants. (source)
• Modified-peptide penetration. in-vitro, Laboratory skin-permeation models. A laboratory delivery study supports a barrier problem for the native peptide. (source)
• Testing cosmetics for identity. in-vitro, Commercial cosmetic creams and serums. Cosmetic ingredient identity and degradation need analytical testing. (source)
• Wrinkle-study evidence review. systematic-review, Human cosmetic studies located through August 2024. The review finds possible benefit but weak comparability. (source)
• Broad skin-peptide meta-analysis. meta-analysis, 19 RCTs of oral or topical peptides; 1,341 participants. A broad peptide meta-analysis does not settle Argireline efficacy. (source)

Gaps: No large independent AH8-only wrinkle trial or direct proof of equivalence to injected botulinum toxin. Pure-peptide concentration, applied amount and delivered dose are often missing or confused with ingredient-solution percentages. No established human systemic half-life, bioavailability, pregnancy, nursing or pediatric safety data. No controlled human injection efficacy or safety trial located; implanted threads have only a case illustration. Long-term safety and persistence after stopping remain uncertain; no evidence-based cycling or microdosing schedule found. No verified standard clinician dose, drug-interaction study, or routine laboratory-monitoring schedule for ordinary topical use. Three completed cosmetic registry studies have no posted results; recent delivery studies have incomplete accessible clinical methods. WADA treatment of this cosmetic ingredient by product and route remains unresolved; no compound-specific official ruling found. No compound-specific Australian scheduling decision, FDA advisory-committee decision or warning letter confirmed. Community frequency labels describe this small search sample; they are not survey-based prevalence estimates. Unpublished manufacturer tests and combination-serum trials may exist beyond the primary human records counted here.

Related to Argireline

• Matrixyl: A topical cosmetic peptide with limited human evidence for making fine lines less visible.
• GHK-Cu: A copper-binding skin peptide with small topical studies and untested systemic injections.

Argireline: the short version

Sources

• Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
• Pyrogen and Endotoxins Testing: Questions and Answers, FDA · 2026
• The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
• Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
• Consumer products: cosmetics, Office for Product Safety and Standards · 2025
• HFP Centers of Excellence 2023-24 Annual Report, FDA · 2024
• Sterile Drug Products Produced by Aseptic Processing — Current Good Manufacturing Practice, FDA · 2004
• Allergens in Cosmetics, U.S. Food and Drug Administration · FDA
• Cosmetic ingredient database, European Commission
• Cosmetics, Therapeutic Goods Administration
• Microbiological Safety and Cosmetics, U.S. Food and Drug Administration · FDA
• Notification of Cosmetics, Health Canada
• Shelf Life and Expiration Dating of Cosmetics, FDA
• Wrinkle Treatments and Other Anti-aging Products, U.S. Food and Drug Administration
• DES-mediated self-assembled polypeptides: Synergistic neuromuscular signaling inhibition for anti-aging., Bai D et al. · Biomaterials advances · 2026

Sources checked: 2026-10-18.

Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.